Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLINYSE:CVMNASDAQ:ENLVNASDAQ:PULM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.12+5.7%$1.11$0.72▼$8.25$8.89M0.35350,227 shs426,691 shsCVMCEL-SCI$2.36-5.6%$6.64$2.26▼$66.60$7.16M0.554,249 shs317,874 shsENLVEnlivex Therapeutics$0.95-0.4%$0.97$0.81▼$1.76$22.47M0.76128,626 shs48,328 shsPULMPulmatrix$8.20-9.8%$6.35$1.78▼$10.40$29.93M1.38133,009 shs48,428 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+5.66%+0.90%+3.23%-30.00%-85.89%CVMCEL-SCI-5.60%-4.07%-72.87%-76.16%-93.78%ENLVEnlivex Therapeutics-0.94%-1.67%-9.53%-21.17%-27.79%PULMPulmatrix-9.79%+27.33%+30.16%+1.49%+336.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics4.274 of 5 stars3.55.00.04.72.70.00.6CVMCEL-SCIN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics3.4077 of 5 stars3.75.00.00.02.70.81.3PULMPulmatrix0.7929 of 5 stars0.05.00.00.03.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,578.57% UpsideCVMCEL-SCI 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.33Buy$10.00957.08% UpsidePULMPulmatrix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BCLI, PULM, CVM, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/24/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/APULMPulmatrix$1.92M15.58N/AN/A$4.93 per share1.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)CVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AENLVEnlivex Therapeutics-$29.07M-$0.73N/AN/AN/AN/A-67.57%-58.45%6/13/2025 (Estimated)PULMPulmatrix-$14.12M-$3.34N/A∞N/A-96.51%-45.97%-30.72%8/11/2025 (Estimated)Latest BCLI, PULM, CVM, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q4 2024ENLVEnlivex Therapeutics-$0.16N/AN/AN/AN/AN/A5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/15/2025Q1 2025PULMPulmatrixN/A-$0.50N/A-$0.50N/AN/A3/31/2025Q4 2024ENLVEnlivex Therapeutics-$0.16-$0.23-$0.07-$0.23N/AN/A3/21/2025Q4 2024PULMPulmatrixN/A-$0.54N/A-$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.050.05CVMCEL-SCI0.661.071.09ENLVEnlivex TherapeuticsN/A9.719.71PULMPulmatrixN/A19.4019.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CVMCEL-SCI12.08%ENLVEnlivex Therapeutics1.02%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics6.70%CVMCEL-SCI9.93%ENLVEnlivex Therapeutics12.28%PULMPulmatrix0.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics407.94 million5.32 millionOptionableCVMCEL-SCI433.03 million64.67 millionOptionableENLVEnlivex Therapeutics7023.65 million18.78 millionOptionablePULMPulmatrix203.65 million3.63 millionNot OptionableBCLI, PULM, CVM, and ENLV HeadlinesRecent News About These CompaniesPulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.comMay 20, 2025 | americanbankingnews.comPulmatrix set for merger with Cullgen, seeks asset divestmentMay 17, 2025 | uk.investing.comPulmatrix Inc.: Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for AssetsMay 15, 2025 | finanznachrichten.dePulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for AssetsMay 15, 2025 | prnewswire.comAspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, PulmocideApril 3, 2025 | theglobeandmail.comPulmatrix Reports 2024 Financials and Merger PlansMarch 25, 2025 | tipranks.comPulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | finanznachrichten.dePulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | prnewswire.comPulmatrix revises bylaws, changes voting standardsFebruary 14, 2025 | msn.comCullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic PainJanuary 23, 2025 | finance.yahoo.comHow to Take Advantage of moves in (PULM)January 11, 2025 | news.stocktradersdaily.comWhen the Price of (PULM) Talks, People ListenDecember 11, 2024 | news.stocktradersdaily.comPulmatrix Inc (PULM) Stock: Surpassing Expectations in the MarketNovember 19, 2024 | bovnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 15, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 15, 2024 | bakersfield.comPULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. MergerNovember 14, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 14, 2024 | globenewswire.comPulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed MergerNovember 14, 2024 | finanznachrichten.dePULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to ShareholdersNovember 14, 2024 | joplinglobe.comFramingham-based biopharma company announces merger agreement with San Diego firmNovember 14, 2024 | wbjournal.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, PULM, CVM, and ENLV Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.12 +0.06 (+5.66%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.09 -0.03 (-2.68%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.CEL-SCI NYSE:CVM$2.36 -0.14 (-5.60%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.37 +0.01 (+0.21%) As of 05/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Enlivex Therapeutics NASDAQ:ENLV$0.95 0.00 (-0.42%) Closing price 05/29/2025 03:59 PM EasternExtended Trading$0.95 0.00 (0.00%) As of 05/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Pulmatrix NASDAQ:PULM$8.20 -0.89 (-9.79%) Closing price 05/29/2025 03:58 PM EasternExtended Trading$8.64 +0.45 (+5.43%) As of 05/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
